Roche Holding Ag Stock Profit Margin

RHHBF Stock  USD 288.23  2.52  0.88%   
Roche Holding AG fundamentals help investors to digest information that contributes to Roche Holding's financial success or failures. It also enables traders to predict the movement of Roche OTC Stock. The fundamental analysis module provides a way to measure Roche Holding's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Roche Holding otc stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Roche Holding AG OTC Stock Profit Margin Analysis

Roche Holding's Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.

Profit Margin

 = 

Net Income

Revenue

X

100

More About Profit Margin | All Equity Analysis

Current Roche Holding Profit Margin

    
  0.19 %  
Most of Roche Holding's fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Roche Holding AG is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
Competition

Based on the latest financial disclosure, Roche Holding AG has a Profit Margin of 0.187%. This is 101.67% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The profit margin for all United States stocks is 114.72% lower than that of the firm.

Roche Profit Margin Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Roche Holding's direct or indirect competition against its Profit Margin to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Roche Holding could also be used in its relative valuation, which is a method of valuing Roche Holding by comparing valuation metrics of similar companies.
Roche Holding is currently under evaluation in profit margin category among its peers.

Roche Fundamentals

About Roche Holding Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Roche Holding AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Roche Holding using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Roche Holding AG based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Other Information on Investing in Roche OTC Stock

Roche Holding financial ratios help investors to determine whether Roche OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Roche with respect to the benefits of owning Roche Holding security.